Member Info for R1CHARDO

MC now below £30M including £10M in the bank. Funding in place for 2 to 3 years at current burn rate. 10 NDAs out with bigger pharmas. Inconclusive P3 trial results on a potential blockbuster Lupus treatment - Lupuzor. AIM madness IMHO. GLA R

I read the problem was with the London Stock Exchange not London and South East...

@ Nolupus - unlike you, I have no particular knowledge of Lupus treatments, nor biotech. I was attracted to IMM about six months ago because I liked the risk/reward ratio. I still do despite the inconclusive P3 result. I carried out detailed research on IMM and that's why I do post here from time to time, but mainly now only to challenge your snide slanted posts, as many others do as well. Regarding your question about active discussions, IMM has the rights to the P140 platform, and bearing in mind the published data about previous research and trials, it would be surprising to me if this very small company was not in discussions with other pharmas. I read big pharmas are desperate for new drugs and acquisition as opposed to invention is currently the preferred route. Up until the P3 trial results were announced, it is my firm belief that IMM, whilst in discussions with others, wanted to get that far on its own, and as RZ said that is a significant feat on its own. The inconclusive results have NOW changed that view and the company has said they are looking for a partner for Lupuzor. (Note not P140 nor the pipeline drugs). From now on the future of IMM and Lupuzor could go any number of ways and we all have opinions on this, but my opinion is that unlike before the P3 announcement, IMM is now seeking to do a deal. What this is I don't know, but in my view if an organisation bought IMM for its current worth of �30m (net of cash) it would be one massive steal. But that's all the market thinks the whole Company is worth today... GLA R

@ Nolupus - even you can do better than that. Your post: "A lot of what you say would make sense, IF, IMM were not actively seeking a partner for the P3 , which they were." What you are trying to imply by that (slanted) post is IMM won't find a partner now because they didn't find one for the P3 trial. I asked you to substantiate your claim because I believe it is untrue. All my posts about a partner relate to AFTER the P3 trial ended inconclusively. Surely even you (who describes yourself as a village idiot) can see the difference. IMO this is typical of the snide slanted way that you post on this BB. The fact is IMM were NEVER looking for a partner for the P3 trial and you Nolupus know this as well as I do. GLA R

@ Nolupus - here we go again. You made the claim and I quote your post to me directly: "A lot of what you say would make sense, IF, IMM were not actively seeking a partner for the P3 , which they were." I asked you to substantiate your claim about a P3 partner, and you have refused to do so asking me to contact the Company. Back up what you claim please or withdraw it. GLA R

@dh2133 not to mention that the trial design was agreed with the FDA.... @ nolupus I don't believe IMM was looking for a partner for P3. News to me. Where does your information come from? GLA

Perhaps Mr Perkin you would be so kind as to copy and paste the complete post where you claim I "were going on about 10 baggers at IMM" although I have no idea what this has to do with SOLO. I have read my posting history and was unable to locate it. Also you claim I bully you and others. Presumably your definition of bullying includes reminding posters of what they previously posted. If that is your view then that's fine ,but it isn't mine. If my posts were against the rules they would be removed. The fact is hundreds or even thousands of people, including myself, have lost money investing in SOLO OIL because the Company has not performed after eight years. You obviously firmly believe that SOLO's fortunes will change, but at the same time you rigorously attack those who hold differing views, or simply point out their experience of investing in SOLO and the quality of opinions expressed on this BB. I think under your definition of bully, that makes you one of the worst.

@Nolupus as you claim you are well researched on IMM then you know the answer as well as I do... The brief answer, as I haven't the time or energy to keep correcting your ill informed posts/slanted question, is Cephalon interfered in the research and negatively affected the P2B trial. When IMM got the rights back from Cephalon following its takeover, IMM kept the $45m which funded their go it alone approach, which RZ is very proud of. Once bitten twice shy etc. Following the inconclusive Topline results the Company has stated they would be better placed to move Lupuzor forward with a partner. Something I agree with. Nolupus - I don't know whether you have heard of the expression "not invented here", but there is a tendency for scientists, engineers and other creative people to hold on to their inventions/discoveries seeing them through rose tinted glasses. SM, RZ and IMM may have been guilty of this, but with $45m of funding I would have taken the same approach. Finally it seems to me from your abundance of slanted and often ill informed posts (testing Lupuzor on pregnant women remember?) that your mindset suggest you suffer from a massive dose of "not invented here" syndrome. I suspect you are in some way involved with a potentially competitive drug, and concerned that Lupuzor is a serious potential threat. That is why you never respond to questions, and ignore the stunning safety profile of Lupuzor. GLA R

@ Kejoglo - Chris Perkin will never accept any responsibility for his posts telling others to BUY LOW, or that selling SOLO shares would be the worst mistake of their lives. Having lost several thousand pounds in SOLO, when I point this out on this BB, he is the one who launches personal attacks, claims I am a bully and ridicules me for other investments I have made in other shares. I am amazed that he thinks he has any credibility as SOLO's SP reaches new lows now almost on a daily basis... t

Very well said Tomozulu. I hold identical viewpoints. Our market cap is currently less than �40m with �10m in the bank. Chicken feed in the world of Pharma. We need a partner to move Lupuzor forward and we know IMM has been talking to larger Pharmas for years (Reference the Annual Reports). Let's not forget Cephalon valued Lupuzor at $450m at the phase 2 stage and put $45m of cash into our Company. Also to those who are targeting Tim's optimism he did make it quite clear before the Topline results were announced that a high Placebo response was what concerned them the most. As they and potential partners analyse these results it is interesting that Lupuzor appears to considerably benefit certain sub-groups. Time will tell but in my view our current market cap is way too low. GLA R

"With a strong balance sheet following the �10 million fund raising in January, ImmuPharma will look to progress its other earlier stage pipeline candidates whilst also exploring other opportunities based on Lupuzor�'s mechanism of action and its potential to expand into other autoimmune conditions." First time the Company has announced this?

it has NEVER done a five bagger has it? try the real figures?

@NorthernMagic IMHO don't put one penny into SOLO. 8 years of failed investments. �30M in and MC now less than half. The BoD has failed to deliver any returns whatsoever other than into their own pockets. No institutional investors, Claim huge reserves etc. in Tanzania but the problem is the cost of extracting is about the same as finding oil on the moon. C Perkin is the company Cheer Person. Told everyone to BUY LOW. Meanwhile SP drops from 80p to 3p. Huge overhang from recent fund raising and LTHs will sell out at the slightest spike. I sold a year ago and the company Cheer Person said it was the biggest mistake in my life. He never apologised. I see you are in SDX. Chalk and cheese. As one poster said SOLO is as nosebleed investment. Only invest here to lose money

opened 1.31. TMXMoney is real time I believe

Google comes up with Stockhouse. Talking about 1.40 CAD.....

@hamila01 Good post and it makes a lot of sense. Also underpins the �10m the placing guys put in. Most posts here discuss Lupuzor and Lupus, but the P140 platform potentially targets other conditions as SM continuously points out. As we know from Benlysta and the other current drug trials, Lupus is a condition which flares and recedes, so any trial is going to be difficult to interpret. The problem with bidders may be the 'Not invented here syndrome' which posters such as Nolupus has in abundance. 'Anything is better than what IMM has.' However this is a mainly a UK issue, and we have already seen the French and German positive press releases. Even at �200-�300m IMM is a steal, but as you say we need a bidding war to get there. GLA R

@ Nolupus Why can't you answer very simple questions? Let's make it easy for you: Pregnant women participating in a trial. Yes or No? Is Lupuzor a better treatment that Benlysta? Yes or No. Is IMM worth more than �30m. Don't repeat yourself -answer the questions. you don't like being exposed do you? No donkeys here only adults. Out of your depth tonight?

@ Nolupus did you miss my post earlier this evening. This BB is awaiting your reply: ' Nolupus may I quote your reply to me: 'Big Pharmas are desperate to find new drugs...Exact ... but drugs that work ..... They have a lot of choices at this time so why pick a drug that has failed ??' But in another of your posts you say the trial failed not the drug. Which is it? You also claim to be familiar with other Lupus drug trails over many years. If that statement is true then why was your first post on this board about pregnant women being excluded? Surely anyone with any familiarity with these type of drug trials knows pregnant women are always excluded? You also make a claim that a new late stage trial would cost 50 to 80 million. You don't state the currency, but please substantiate this claim. You also make the claim that Benlysta worked better in its P3 trials than Lupuzor, although it appears to have some significant side effects (which you never mention). Again please support your claim. The point here is that the P3 trial was inconclusive and needs further study. The P140 platform potentially offers effective treatments for other conditions, again without significant side effects. IMM holds significant patents going into the 2030s. IMM did a deal with Cephalon ten years ago worth up to $450m when the P140 platform was far less advanced. We know IMM has been in discussions with a number of big Pharma companies for some time. After the Cephalon debacle they decided to go it alone, but with the inconclusive P3 result this has now changed, and they have clearly indicated that partnership/takeover is their preferred route forward. A deal could be announced tomorrow and it won't be at 30p a share... GLA R

I second that. PW needs to bring shareholders up to date on discoveries and reserves as I think some of this is getting lost. He also needs to update us on gas sale agreement timings in Morocco, and debt payments in Egypt. I believe the market needs clear evidence that SDX is delivering. Only because so many investors have been badly burnt by O&G companies in the past. GLA R

' Nolupus may I quote your reply to me: 'Big Pharmas are desperate to find new drugs...Exact ... but drugs that work ..... They have a lot of choices at this time so why pick a drug that has failed ??' But in another of your posts you say the trial failed not the drug. Which is it? You also claim to be familiar with other Lupus drug trails over many years. If that statement is true then why was your first post on this board about pregnant women being excluded? Surely anyone with any familiarity with these type of drug trials knows pregnant women are always excluded? You also make a claim that a new late stage trial would cost 50 to 80 million. You don't state the currency, but please substantiate this claim. You also make the claim that Benlysta worked better in its P3 trials than Lupuzor, although it appears to have some significant side effects (which you never mention). Again please support your claim. The point here is that the P3 trial was inconclusive and needs further study. The P140 platform potentially offers effective treatments for other conditions, again without significant side effects. IMM holds significant patents going into the 2030s. IMM did a deal with Cephalon ten years ago worth up to $450m when the P140 platform was far less advanced. We know IMM has been in discussions with a number of big Pharma companies for some time. After the Cephalon debacle they decided to go it alone, but with the inconclusive P3 result this has now changed, and they have clearly indicated that partnership/takeover is their preferred route forward. A deal could be announced tomorrow and it won't be at 30p a share... GLA R